key: cord-0911627-9cxwrwpb
authors: Aleem, Samia; Wohlfarth, Megan; Michael Cotten, C.; Greenberg, Rachel G.
title: Infection control and other stewardship strategies in late onset sepsis, necrotizing enterocolitis, and localized infection in the neonatal intensive care unit
date: 2020-10-12
journal: Semin Perinatol
DOI: 10.1016/j.semperi.2020.151326
sha: 13e5283b5be6db6df8062ebf3ca2fcce703f95a7
doc_id: 911627
cord_uid: 9cxwrwpb

Suspected or proven late onset sepsis, necrotizing enterocolitis, urinary tract infections, and ventilator associated pneumonia occurring after the first postnatal days contribute significantly to the total antibiotic exposures in neonatal intensive care units. The variability in definitions and diagnostic criteria in these conditions lead to unnecessary antibiotic use. The length of treatment and choice of antimicrobial agents for presumed and proven episodes also vary among centers due to a lack of supportive evidence and guidelines. Implementation of robust antibiotic stewardship programs can encourage compliance with appropriate dosages and narrow-spectrum regimens.

Perinatal Quality Care Collaborative reported that across units, antibiotic treatment ranges from 2.4% to 97 .1% of patient-days. 9 In one study, it was found that 35% of infants receiving antibiotics for over 72 hours received them inappropriately. 11 The study defined inappropriate antibiotic therapy to include inappropriate initiation, continuation, type, and nonadherence to the Centers for Disease Control and Prevention (CDC) 12- Step program to prevent antimicrobial resistance. 11 Forms of misuse of antibiotics in this study included the use of gentamicin for a gentamicin-resistant pathogen, continued use of 2 agents when a single agent is adequate, and the use of a carbapenem for empiric treatment of LOS (without evidence of NEC or multi-drug resistance). 11 Cosgrove et al. found that 28% of antimicrobial treatments did not follow the CDC's recommended 12 steps for prevention of antimicrobial resistance leading to the overuse of antibiotics in the NICU. 25 The variability in neonatal antimicrobial drug dosing clearly highlights the need for antibiotic stewardship strategies. In a survey of antibiotic guidelines across 44 French NICUs, up to 32 different dosage regimens per drug were identified for 41 antibiotics. 26 Another study spanning 89 NICUs from 21 countries in Europe found wide variations in antibiotic dosing, with both under-and over-dosing when compared with the recommendations in the British National Formulary for Children. 27 These variations stem from the lack of high quality evidence for dosing in neonates; most neonatal dosing is extrapolated from adult studies and is adjusted based on weight. 28, 29 This is suboptimal, as infants display distinctly different pharmacokinetics (PK) that vary based on gestational and postnatal age. 30 Under-dosing of antibiotics leads to ineffective treatment of infection and promotes the development of microbial resistance, whereas over-dosing results in toxicity and compromised safety. 31 Multiple PK studies of antibiotics have been performed in infants to define dosing that optimizes therapeutic exposures for infants ( Table 1) .

Strategies for antibiotic stewardship: Adoption of preventive strategies to reduce the incidence of LOS and LOM are the first step to reducing prolonged antibiotic use: strategies reported to have the most marked impact involve of a bundle of care focusing on a combination of hand washing, central line management, and infection control practices. [32] [33] [34] A second key step in appropriate antibiotic use for LOS/LOM is the choice of antibiotic. In a survey of neonatologists' practice for infants with suspected LOS, 60% of clinicians prescribed vancomycin for empiric therapy. 35 The choice of vancomycin is directed by concerns for methicillin-resistant Staphylococcus aureus (MRSA) infection, and the predominance of CoNS in the setting of LOS. 36 However, there are multiple studies showing that restricting empirical vancomycin use does not result in increased mortality or morbidity. [37] [38] [39] [40] Chiu et al reported the effectiveness of implementing a restrictive vancomycin use guideline at 2 tertiary care centers. 38 The investigators waited until CoNS susceptibility results were available prior to initiating vancomycin, and were able to safely and successfully decrease vancomycin use without an increase in attributable morbidity or mortality. 38 One center retrospectively found no change in mortality or morbidity after changing the standard empiric treatment for LOS from vancomycin and cefotaxime to oxacillin and gentamicin. 40 Thus, it is prudent to use an antistaphylococcal penicillin, such as oxacillin or nafcillin, along with an aminoglycoside for the initial empiric treatment of LOS. 7, 36, [38] [39] [40] [41] [42] [43] Vancomycin should be considered judiciously in areas where MRSA is prevalent, or if the culture is positive for CoNS. [41] [42] [43] In the setting of a negative blood culture, with optimal collection technique, discontinuation of antibiotics should be considered. 44 The use of biomarkers, such as acute phase reactants, cytokines and chemokines, for the diagnosis of LOS and to guide length of therapy is promising. 45 However, most of these biomarkers are non-specific, and would be better used for their negative predictive value. 45 If meningitis is suspected, ideally a lumbar puncture should be performed and treatment should be initiated immediately after cerebrospinal fluid is obtained. 46 The most commonly prescribed antibiotics for late-onset meningitis are vancomycin, gentamicin, cefotaxime, and ampicillin. 47, 48 The recommended regimen to treat LOM in infants includes a combination of an antistaphylococcal antibiotic (nafcillin or vancomycin) plus a third-generation cephalosporin with or without aminoglycosides. 43, 49 Traditionally, infants with meningitis are treated with empirical antibiotics for 14 -21 days. 43 It is recommended that infants with meningitis caused by Gram-negative bacteria be treated with antibiotics for at least 21 days. 49, 50 Lastly, antibiotic stewardship programs can improve appropriate antibiotic use by implementing interventions that decrease infection related mortality and morbidity without increasing antibiotic resistance. One recommended intervention is daily prospective audit and feedback. Daily prospective audit and feedback includes accessing the needs for antimicrobial therapy of a patient to optimize treatment. This intervention involves a relationship between the physician and the prescribing provider such as an infectious disease specialist or a pharmacist specializing in pediatric antibiotic stewardship. In a study conducted by Thampi et al., antibiotic usage measured as days of treatment per 1000 patientdays decreased by 14% with daily prospective audit and feedback. 51 The proportion of admitted babies who received antibiotics also decreased (63% versus 59%). 51 Interventions such as education about the risks of broad-spectrum antibiotic use and adjusting empiric antibiotic regimens have also been found to reduce the use of broad-spectrum antibiotic usage. 38, 52 Nzegwu et al. demonstrated a significant reduction in ampicillin days of antibiotic therapy (DOT) when educational methods were combined with prospective audit and feedback. 53 Chiu et al. showed that by creating guidelines for the use of vancomycin, the use of the antibiotic could be decreased by 40-49%. 38 Other methods of intervention include setting hard stops to antibiotic usage and utilizing risk calculators. Tzialla et al. found that DOT was decreased by 27% with the implementation of an automatic stop to antibiotic treatment when cultures are sterile for 48 hours, as well as a five-day automatic stop to antibiotic treatment for culturenegative sepsis or suspected pneumonia. 54 Predictive model for risk stratification such as the use of a risk calculator has decreased antibiotic usage for EOS among near-term and full term neonates by 42%. 55 More research into the feasibility of determining the risk of LOS and LOM using a risk calculator is necessary.

Epidemiology of NEC: NEC is an acquired gastrointestinal inflammatory disease, and is a leading cause of death in extremely low birth weight (ELBW) infants. 56 The incidence of NEC has remained relatively stable and, in some reports, appears to be slightly decreased over the past decade. [57] [58] [59] In extremely preterm infants born between 22 and 28 weeks gestational age, the incidence of NEC increased from 7% in 1993, to 13% in 2008, before decreasing to 9% in 2012. 58 In a recent report of Vermont Oxford Network data, the rate dropped from 6.6 -4.0% among VLBW inborn infants, and from 10.4% to 6.6% among ELBW inborn infants from 2008 to 2017. 59 Mortality secondary to NEC has also increased over the years, and went from 23% in 2000 -2003, to 30% in 2008 -2011. 56 Infants who do survive, particularly ELBW infants who undergo surgical intervention, have long-term impairments including growth delay and poor neurodevelopmental outcomes. 60 Etiology of NEC and rationale for antibiotic therapy: The exact etiology of NEC is unknown and it is considered to be multifactorial in origin. In addition to immaturity of the intestinal function secondary to prematurity, intestinal ischemia, type of enteral feeds, and importantly, aberrant bacterial colonization play a role. 61, 62 In up to 35% of cases of NEC, concurrent bacteremia is documented. 63 Although no specific microorganism has been consistently identified to be causative, a wide range of pathogens are associated with NEC. 63 These include Escherichia coli (E. coli), Klebsiella spp, Enterobacter spp, Pseudomonas spp, Salmonella spp, Clostridium perfringes, Clostridium difficile, Clostridium butyricum, coagulase-negative staphylococci, Enterococcus spp, coronavirus, rotavirus and enterovirus. 63 Early stool colonization with Clostridium perfringens 64 

Enterobacteriaceae among VLBW infants has been associated with later development of NEC. 65 Poor early antibiotic stewardship may contribute to development of NEC: Premature infants almost universally receive broad-spectrum antibiotics after birth, and many receive prolonged courses to treat culture-positive or presumed culture-negative sepsis. 66, 67 Prolonged exposure to antibiotics early in life increases the risk of abnormal intestinal bacterial colonization. 68, 69 A retrospective cohort analysis of ELBW infants born between 1998 -2001 admitted in NICHD Neonatal Research Network (NRN) centers found an association between a prolonged initial antibiotic course of >5 days and an increased risk of developing NEC. 2 Other smaller studies also supported this association. 4, 70, 71 A more recent study of over 5000 infants from the same network born between 2008-2014 did not find a significant association between early prolonged antibiotics of NEC. 72 This is likely related to a decrease in the proportion of early prolonged antibiotics being used, as well as more widespread use of human donor milk, maternal breast milk, and probiotics ( Table 2) . 72 Medical therapy for NEC and antibiotic stewardship: Treatment strategy for NEC depends on severity of illness and may be medical or surgical in nature. 73, 74 Medical therapy for NEC includes broad-spectrum antibiotics with coverage for anaerobic intra-abdominal bacteria. 63, 75 However, there is a paucity of data guiding the specific medical therapy for NEC, leading to wide practice variation in the antibiotic choice and duration of administration. 76 In a small randomized, controlled trial of 42 premature infants with radiographic evidence of NEC, there was no difference seen in the incidence of intestinal perforations or mortality in those who received a combination of ampicillin, gentamicin, and clindamycin compared with those who only received ampicillin and gentamicin. 77 However, a higher rate of intestinal strictures was found in the group receiving clindamycin. 77 In a retrospective study of 6737 VLBW infants born at Pediatrix Medical Group NICUs Infants who received anaerobic antibiotics, had a higher rate of intestinal strictures [odds ratio (OR) 1.73; 95% CI, 1.11 -2.72]. When restricting to infants with surgical NEC, however, anaerobic antimicrobial therapy had less mortality (OR 0.71; 95% CI, 0.52 -0.95). There was no improvement in outcomes of infants with medical NEC conditional to anaerobic antimicrobial therapy. 78 In a recent retrospective cohort study of 4089 infants using the same database and overlapping infants, investigators used a PK simulation model to determine the effect of the highest estimated clindamycin exposure quartile and found a reduced odds of death with higher clindamycin exposure (OR 0.67; 95% CI 0.46 -0.98). 79 Alternative treatment regimens have been explored. One randomized controlled trial of 20 infants evaluated the role of oral gentamicin added to parenteral ampicillin and gentamicin. In this study, no significant difference was found in mortality, intestinal perforations or strictures between the comparison groups. 80 One study from the 1980s compared alternative treatment regimens in 90 infants with clinical and radiographic evidence of NEC. 81 46 infants received ampicillin (100 mg/kg/day) and gentamicin (5 -7.5 mg/kg/day), while the other 44 infants were treated with cefotaxime (150 mg/kg/day) and vancomycin (30 -45 mg/kg/day). All antibiotics were administered for 7 -10 days.

Infants with a birthweight <2200 g who received the cefotaxime/vancomycin regimen were less likely to die, and had a lower risk of culture-positive peritonitis. 81 Similar outcomes with either antibiotic combination were seen in infants with birthweights > 2200 g. 81 The recently concluded antibiotic safety (SCAMP) trial compared the safety of various antibiotic regimens for complicated intra-abdominal infections, and provides valuable information regarding the safety and efficacy of the most commonly used antimicrobials for NEC. 82 This partially randomized trial compared the following antibiotic combinations: ampicillin/gentamicin/metronidazole, ampicillin/gentamicin/clindamycin and piperacillintazobactam/gentamicin. The preliminary results showed that all 3 drug regimens were well tolerated, and no clinically significant difference in adverse events, including death, intestinal strictures or perforations, was observed. Thus, even though antibiotics are the mainstay of therapy for NEC, at present, there is no conclusive evidence to suggest superiority of one anaerobic antimicrobial over the other, despite their widespread use. In the interest of antibiotic stewardship, we recommend using the narrowest appropriate coverage, especially in the setting of positive blood or urine cultures. In many cases, the narrowest appropriate coverage will be ampicillin/gentamicin/metronidazole, which provides coverage against aerobic and anaerobic organisms with some penetration to the central nervous system. The recommended length of broad-spectrum parenteral antibiotic therapy is 7 -10 days. 74 However, some centers reportedly administer antibiotics for 10 -14 days, which may be excessive in cases of mild disease. 63 Therefore, we recommend limiting antibiotic duration to 7 -10 days, and extending it only in cases of clinical deterioration.

Epidemiology of UTIs: UTIs are common among infants admitted to the NICU, with an incidence of 3 -25% among VLBW infants. [83] [84] [85] [86] UTIs typically occur later during the course of an infant's NICU hospitalization; they are rarely detected in the first 72 hours of age (0 -1%), and no cases have been reported to occur in the first 24 hours of age, even in premature infants. 85, 87 Structural renal abnormalities increase the risk of neonatal UTIs, an estimated 20% of cases are associated with vesicoureteral reflux (VUR). 88, 89 Term and preterm infants with UTIs commonly present with poor feeding, emesis, lethargy, and fever (> 38°C), and over 50% of preterm infants with UTIs also present with respiratory symptoms, such as tachypnea, hypoxia and apnea. 86, 90, 91 Infants with UTIs are at risk for concomitant bacteremia and meningitis; in one study of infants <121 days of age, 127/976 (13%) episodes of UTI had concordant bacteremia, and 2/77 (3%) UTI episodes also had meningitis. 92 This concordance is more likely to occur in infants born at <26 weeks gestation. 92 In ELBW infants, Candida

UTIs are associated with death and neurodevelopmental impairments. 93 Etiologic organisms for UTI in the NICU: Nearly 80% of cases of UTIs are caused by E. coli, making it the most common causative organism in all age groups, including the neonatal period. 88, [94] [95] [96] Male infants with VUR are more likely to present with less common pathogens, such as Enterobacter aerogenes, Pseudomonas aeruginosa, and Klebsiella oxytoca. 88, 90 Studies from NICUs have reported a high incidence of CoNS UTIs. 92, 97 In a large retrospective study of over 500,000 preterm and term infants admitted to the NICU, CoNS was isolated in 14% of catheterized urine cultures in infants with UTIs, and was concordant with a blood culture in 18% of cases. 92 In ELBW infants, Candida UTIs occur commonly. 93 In a prospective cohort study of 1515 ELBW infants (birthweight < 1000g), 137 infants were identified as having invasive candidiasis, of which 52/137 (38%) infants were diagnosed with candiduria from urine specimens collected by catheterization or suprapubic aspiration. 98 In a study of hospital-acquired UTIs occurring in infants admitted in the NICU, Candida spp. were responsible for 42% of infections. The mean gestational age of these infants was 26 weeks, which was significantly lower than the gestational age of infants diagnosed with a bacterial UTI (28 weeks). 99 Diagnosis of UTI: UTIs are variably defined in NICUs. 100 Variable definitions and diagnoses lead to unnecessary antibiotic use, which represents an opportunity to improve antibiotic stewardship in the setting of suspected UTIs. A commonly used definition is the growth of a single known organism from a catheterized urine sample at: > 50, 000 colony-forming units (CFU) per milliliter, or > 10, 000 CFU/mL in association with a positive dipstick test or urinalysis. 88, 94, 101 The 3 common methods of collecting urine in infants are: sterile bag collection, urinary catheterization, and suprapubic aspiration. Although sterile bag collection is non-invasive and easy to perform, it does have high contamination rates. A prospective study of children < 24 months found that of the 7584 urine cultures obtained, 63% of bagged specimens were contaminated, compared to 9% of samples obtained via catheterization. 102 Given the high falsepositive culture prevalence of UTIs with bagged specimens, urethral catheterization and suprapubic aspiration are the preferred methods of collection. However, these methods are more invasive, and given the perceived pain associated with the procedure, along with limited feasibility and relatively lower success rates of performing these in small and critically ill infants, sterile bag collection is used more frequently in clinical practice. 103, 104 This is problematic, as clinicians may find it difficult to ignore a 'positive' culture, leading to unnecessary antibiotic treatments. 105 Moreover, the absence of nitrites and leukocyte esterase on dipstick are unreliable in the infant population because of small bladders and frequent micturition. 106 Based on the available data, we recommend obtaining urine via catheterization whenever possible, and avoidance of bag collection for cultures. If the infant is being treated for sepsis regardless of urine culture results, bagged specimens may be considered to help tailor therapy in the presence of bacterial growth.

Treatment of UTI: Before committing to treatment for a UTI, clinicians should take method of urine collection into consideration. Most urine parameters in infants are misleading, leading to misdiagnoses and antibiotic overuse, thus optimizing specimen collection to avoid contaminants provides an opportunity for antibiotic stewardship. Initial management for UTIs in the NICU consists of parenteral broad spectrum therapy, typically ampicillin and gentamicin, or ampicillin and a 3 rd generation cephalosporin, followed by narrowing of the regimen based on culture sensitivity results. 107 In the US, the reported incidence of ampicillin resistant neonatal E. coli strains is as high as 75%, and resistance to gentamicin is as high as 12-17%. 108,109 A retrospective study of 73 cases of neonatal UTIs in Iran reported over 90% resistance of E. coli strains against ampicillin. 110 Despite this, a clinical response was seen in 50% of infants, suggesting discordance between in vivo and in vitro activity, or higher urinary concentration of the drug. 110, 111 The American Academy of Pediatrics (AAP) recommends 7 -14 days of antimicrobial therapy for UTIs in children between the ages of 2 -24 months. 112 Similar guidelines do not exist for infants less than 2 months of age, especially for those born prematurely and admitted to the NICU. Given the lack of data regarding the safety, bioavailability, and efficacy of oral antibiotics in extremely premature infants, parenteral therapy is preferred for 7-14 days, depending on clinical status and other complications.

Definition of VAP: The CDC defines VAP as an episode of pneumonia in invasively ventilated patients that occurs at least 48 hours after initiation of mechanical ventilation. 113 Although this definition does not outline specific criteria for diagnosis in the newborn period, most studies in the NICU also use this definition. 114 The exact incidence of VAP in the NICU is difficult to estimate because of the lack of wellestablished diagnostic criteria in this population. The incidence of VAP in developed countries is reported between 2.7 to 10.9 cases per 1000 ventilator days, whereas in developing countries it may reach up to 37.2 episodes per 1000 ventilator days. [115] [116] [117] [118] In a study of 12 NICUs, the incidence of VAP in infants weighing less than 1000 g was 0 -21.2 per 1000 ventilator days. 119 Epidemiology of VAP: Factors that place infants in the NICU at a higher risk for developing VAP include prolonged mechanical ventilation, and a functionally immature respiratory and immune system. A prospective cohort study of 742 neonates found that low birth weight and mechanical ventilation were the main risk factors for the development of VAP. 120 In another prospective cohort study of extremely preterm infants born <28 weeks gestation, with a birthweight < 2000g, bloodstream infection was found to be an independent risk factor for VAP, after adjustment for the duration of endotracheal intubation. 118 Moreover, VAP was also an independent risk factor for mortality. No one particular organism has been linked to VAP. In the above mentioned prospective study of extremely preterm infants, 94% of cases of neonatal VAP were secondary to gram negative organisms. 118 Similar findings were reported in a single-center retrospective study of 259 infants in China, in which 82% of the VAP cases were due to gram-negative organisms. 121 Other authors have found that VAP is mostly polymicrobial in nature. 122 Of note, these studies are limited by the fact that samples were retrieved by endotracheal aspiration as opposed to invasive sampling of the lower respiratory tract, and therefore may represent oropharyngeal colonization instead of true infection.

avoid unnecessary antibiotic therapy. The lack of diagnostic criteria for VAP in infants makes accurate diagnosis difficult. The CDC criteria have not been validated in infants, making the diagnosis in clinical practice open to subjective interpretation. 114 Moreover, differentiating pneumonia from underlying chronic lung disease from radiographs of LBW infants is difficult. 123 Bronchoalveolar lavage (BAL) samples, or those taken from a protected specimen brush, are invasive tests used to diagnose VAP in adults. 124 Given the small size of the airways, these tests are impractical in infants. Instead, tracheal aspirate cultures and Gram stains are used to evaluate suspected pneumonia in infants. These tests have low specificity, sensitivity, and positive predictive value for distinguishing between VAP and tracheal colonization. 125 In a cohort study of VLBW infants, VAP, defined by the presence of pathogens in the trachea or blood, as well as clinical and radiographic findings, was diagnosed in only 10% of infants with purulent tracheal aspirates. 126 The presence of white blood cells on tracheal aspirates has also been shown to have low specificity (54%) and sensitivity (67%) for VAP, even when there is bacterial growth on culture. 127 Nonbronchoscopic BAL (NB-BAL) or blind BAL has emerged as a more reliable and feasible sampling method to diagnose VAP in infants. 128 In this method, a suction catheter is advanced into the lower airway until resistance is met. Saline lavage is then performed to collect a sample. 128 The utility of this method has been described in an observational, prospective study of 198 preterm and term infants who were intubated for > 48 hours. 16 infants who were clinically suspected to have VAP had a blind BAL performed, and no complications associated with the procedure were reported. 115 Moreover, the authors report a lower incidence of polymicrobial etiology, likely related to reduced contamination from a more invasive and sterile technique. 115 In another observational study using the NB-BAL technique in ventilated preterm infants, airway neutrophil counts of those diagnosed with VAP or congenital pneumonia were compared to those without infection. 129 The median number of neutrophils in infants diagnosed with pneumonia was significantly higher than those without (24 cells/field vs 4 cells/field).

This difference was only observed after the first 2 days on mechanical ventilation. 129 The authors also performed receiver operator characteristics analysis for neutrophil count to diagnose pneumonia.

Within the first 2 days of mechanical ventilation, an airway neutrophil count had moderate accuracy of diagnosing pneumonia, with 4 cells/field having a 90% sensitivity, and 59% specificity for diagnosis.

Unfortunately, after 2 days of mechanical ventilation, neutrophil count was found to be no longer reliable. 129 The NB-BAL method has not been adopted over tracheal aspirates in neonatal practice, but is a promising and well tolerated method to reduce high false positive rates of VAP, and over-treatment.

We recommend avoidance of tracheal aspirates, and instead use of the blind BAL/NB-BAL approach along with the CDC's diagnostic criteria. 113 Treatment for VAP: Given the controversy in diagnosis of neonatal VAP, there is also no clear consensus regarding optimal treatment regimens or duration of antimicrobials. Treatment for VAP involves initial empiric therapy with broad spectrum antibiotics, followed by de-escalation once culture results are available, or discontinuation when VAP is no longer suspected. When selecting initial therapy, clinicians should be aware of the antibiotics that have previously been administered, as well as prior culture results and colonization data. The use of aerosolized antibiotics has been studied comprehensively in pediatric patients with cystic fibrosis. The FDA approval for the use of inhaled tobramycin in children is limited to patients with cystic fibrosis who are known to be colonized with Pseudomonas aeruginosa. 130 The advantageous effects of inhaled tobramycin in this population was demonstrated in 2 randomized, multi-centered, placebo-controlled clinical trials. Children who received inhaled tobramycin had significant improvement in lung function, compared to those who did not. Additionally, there was a significant reduction in the number of Pseudomonas aeruginosa colonies in the sputum of children in the treatment group. 131 Although inhaled antibiotics are being used in infants, there is little data from this population to support this and its' use is extrapolated from studies in the pediatric and adult population. Small single center studies have reported successful use of aerosolized colistin in the treatment of Acinetobacter VAP. 132, 133 Clinical trials are needed to determine the efficacy of inhaled antibiotic therapy in this population. At this time, no guidelines exist regarding empiric coverage or length of treatment for VAP in infants. One study found that in term and late preterm infants, 4 days of antibiotic therapy along with a 24-hour observation period was comparable to 7 days of therapy. 134 The same institution reported a decrease in the days of antibiotic therapy for pneumonia by recommending 5 days of treatment for suspected pneumonia during an antibiotic stewardship intervention study. 7 During the intervention period, there was no increase in short-term clinical safety outcomes. 7 Based on this, in those diagnosed with neonatal VAP, parenteral antimicrobial therapy can be given for 5 -7 days, which can be modified based on clinical status and resistance patterns. 7, 135 Therapy should be based on clinical status and culture results, ideally obtained from the lower airways.

The CDC has published guidelines for the prevention of VAP, which are also applicable to the neonatal population. 113 Since most VAPs are caused by oropharyngeal flora, the CDC recommends suctioning of the oropharynx prior to adjustment or removal of the endotracheal tube. 113 Traditional open endotracheal suctioning involves disconnection from the ventilator and is associated with arrhythmias, increased intracranial pressure and mean blood pressures in infants. 136 Closed suction systems were introduced in the 1980s, and have the potential to reduce environmental contamination of the endotracheal tube. On the other hand, closed suctioning may increase risk of bacterial contamination from pooled secretions re-introduced into the system with repeated suctioning. 124 In a randomized study of 133 LBW infants comparing closed and open suctioning systems, no differences were found in the rates of VAP or bloodstream infection between the two groups. 137 91% of nurses in the study deemed the closed suctioning system to be easier, less time-consuming, and better tolerated by the infants. 137 At this time, the CDC does not recommend one system over the other. Since prolonged intubation is a risk factor for VAP, reducing days on invasive mechanical ventilation by assessing for extubation readiness, and the use of noninvasive measures such as high flow cannulas and nasal continuous positive airway pressure have been shown to reduce rates of VAP. 138, 139 In a prospective study aimed to reduce NICU nosocomial infection rates, aggressive weaning off the ventilator, in addition to other measures, led to the decrease in VAP rates from 3.3 to 1.0 per 1000 ventilator days. 140 Lastly, enforcement of strict hand hygiene policies is one of the most important measures to reduce nosocomial infections such as VAP. In a prospective study lasting 2 years, increased hand hygiene compliance from 43% to 80% resulted in the reduction of VAP rates from 3.35 to 1.06 infections per 1,000 patient days. 141 Reducing the number of ventilated days and implementing hygiene techniques is the cornerstone in the prevention of VAP.

 LOS, LOM, NEC, UTIs and VAP are notable late onset infections in the NICU, and approximately 1/4 th of antibiotic courses administered during this period are given inappropriately. 11, 58  Gram-positive bacteria are the most common pathogens causing LOS and LOM. 23, 43 Initial antibiotic treatment for LOS includes an antistaphylococcal penicillin with an aminoglycoside; in areas where MRSA is prevalent, vancomycin should be considered. [41] [42] [43]  Meningitis is diagnosed via a lumbar puncture, and treatment of LOM includes a combination of an antistaphylococcal antibiotic plus a third-generation cephalosporin with or without aminoglycosides. 43 Traditional length of treatment is for 14 -21 days, and in cases of Gramnegative meningitis is 21 days. 43, 49, 50  The incidence of NEC has slightly decreased over time, and its etiology is considered to be multifactorial, with aberrant bacterial colonization shown to play a role. 59, 61, 62  Standard medical therapy for NEC includes broad-spectrum antimicrobials; however, there is a lack of data guiding specific antibiotic choice and duration, and various studies have not shown superiority of one anaerobic microbial over the other. 63, 75, 76, [79] [80] [81] [82]  We recommend using the narrowest appropriate coverage for the medical treatment of NEC, especially in the setting of positive blood or urine cultures for 7 -10 days, and extending it in cases of clinical deterioration. 74  The varying diagnostic techniques for UTIs are an opportunity for antibiotic stewardship, and the gold standard for urine collection is via urethral catheterization. 100  Initial management for UTIs in the NICU consists of parenteral broad spectrum therapy, typically ampicillin and gentamicin, or ampicillin and a 3 rd generation cephalosporin, followed by narrowing of the regimen based on culture sensitivity results. 107 Therapy is preferred for 7 -14 days, based on clinical status and other complications. 112  The lack of diagnostic criteria for VAP makes accurate diagnosis and treatment difficult. In cases of clinically suspected VAP, we recommend avoidance of routine tracheal aspirates for the diagnosis of VAP. The more recently published blind BAL/NB-BAL approach may offer more specific diagnosis, and the CDC's diagnostic criteria should also be considered. 113  In those diagnosed with VAP, we recommend parenteral antimicrobial therapy for 5 -7 days, which can be extended based on clinical status and resistance patterns. 7, 135  Comprehensive antibiotic stewardship programs, bundles of preventive care strategies, and improved diagnostic methods are the key to reducing prolonged antibiotic use for these indications. 

Medication use in the neonatal intensive care unit

Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants

The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants

Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants

Prolonged early antibiotic use and bronchopulmonary dysplasia in very low birth weight infants

Antibiotic use for presumed neonatally acquired infections far exceeds that for central line-associated blood stream infections: an exploratory critique

Reducing unnecessary antibiotic use in the neonatal intensive care unit (SCOUT): a prospective interrupted time-series study

Use of antimicrobial agents in United States neonatal and pediatric intensive care patients

Neonatal intensive care unit antibiotic use

Newborn Antibiotic Exposures and Association With Proven Bloodstream Infection

Antibiotic use in neonatal intensive care units and adherence with Centers for Disease Control and Prevention 12 Step Campaign to Prevent Antimicrobial Resistance

Late-onset Sepsis in Extremely Premature Infants

Vancomycin for prophylaxis against sepsis in preterm neonates

Early and late onset sepsis in very-low-birth-weight infants from a large group of neonatal intensive care units

Morbidity and mortality of coagulase-negative staphylococcal sepsis in very-low-birth-weight infants

Pathogens associated with sepsis in newborns and young infants in developing countries

Canadian Neonatal N. Risk Factors and Outcomes of Late-Onset Bacterial Sepsis in Preterm Neonates Born at < 32 Weeks' Gestation

Bacterial meningitis in the United States

Neonatal Meningitis: Overcoming Challenges in Diagnosis, Prognosis, and Treatment with

Incidence, etiology, and outcome of bacterial meningitis in infants aged <90 days in the United kingdom and Republic of Ireland: prospective, enhanced, national population-based surveillance

Lancet Neonatal Survival Steering T. 4 million neonatal deaths: when? Where? Why?

To tap or not to tap: high likelihood of meningitis without sepsis among very low birth weight infants

Neonatal bacterial meningitis: an update. Paediatrics and Child Health

Impact of different methods of feedback to clinicians after postprescription antimicrobial review based on the Centers For Disease Control and Prevention's 12 Steps to Prevent Antimicrobial Resistance Among Hospitalized Adults

Therapeutic guidelines for prescribing antibiotics in neonates should be evidence-based: a French national survey

High variability in the dosing of commonly used antibiotics revealed by a Europe-wide point prevalence study: implications for research and dissemination

Drug disposition and clinical practice in neonates: cross talk between developmental physiology and pharmacology

Clinical trials in neonatal sepsis

Antimicrobial dosing in neonates

Antibiotic resistance in neonatal intensive care unit pathogens: mechanisms, clinical impact, and prevention including antibiotic stewardship

Combined use of alcohol hand rub and gloves reduces the incidence of late onset infection in very low birthweight infants

Statewide NICU central-line-associated bloodstream infection rates decline after bundles and checklists

An evidence-based catheter bundle alters central venous catheter strategy in newborn infants

Evaluation and treatment of neonates with suspected lateonset sepsis: a survey of neonatologists' practices

Challenges and opportunities for antibiotic stewardship among preterm infants

No survival benefit with empirical vancomycin therapy for coagulase-negative staphylococcal bloodstream infections in infants

Effectiveness of a guideline to reduce vancomycin use in the neonatal intensive care unit

Decreasing vancomycin utilization in a neonatal intensive care unit

Fulminant late-onset sepsis in a neonatal intensive care unit, 1988-1997, and the impact of avoiding empiric vancomycin therapy

Clinical microbiology of bacterial and fungal sepsis in very-low-birthweight infants

Antibiotics in neonatal infections: a review

Choice and duration of antimicrobial therapy for neonatal sepsis and meningitis

Relevance of Neonatal Anaerobic Blood Cultures: New Information for an Old Question

Biomarkers for late-onset neonatal sepsis: cytokines and beyond

When to Include a Lumbar Puncture in the Evaluation for Neonatal Sepsis

Early and late onset sepsis in late preterm infants

Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network

Bacterial meningitis in children

Practice guidelines for the management of bacterial meningitis

Prospective audit and feedback on antibiotic use in neonatal intensive care: a retrospective cohort study

An antibiotic policy to prevent emergence of resistant bacilli

Implementation of an Antimicrobial Stewardship Program in a Neonatal Intensive Care Unit

Antimicrobial therapy in neonatal intensive care unit

Implementation of the Sepsis Risk Calculator at an Academic Birth Hospital

Causes and timing of death in extremely premature infants from

Mortality and neonatal morbidity among infants 501 to 1500 grams from

Care Practices, Morbidity, and Mortality of Extremely Preterm Neonates

Modifiable Risk Factors in Necrotizing Enterocolitis

Neurodevelopmental and growth outcomes of extremely low birth weight infants after necrotizing enterocolitis

Intestinal microbiota and its relationship with necrotizing enterocolitis

Necrotizing enterocolitis: recent scientific advances in pathophysiology and prevention

Necrotizing enterocolitis

Early intestinal bacterial colonization and necrotizing enterocolitis in premature infants: the putative role of Clostridium

Duodenal microflora in very-low-birth-weight neonates and relation to necrotizing enterocolitis

Reported medication use in the neonatal intensive care unit: data from a large national data set

Temporal Trends and Center Variation in Early Antibiotic Use Among Premature Infants

Stool microflora in extremely low birthweight infants

Early empiric antibiotic use in preterm infants is associated with lower bacterial diversity and higher relative abundance of Enterobacter

Empirical antibiotic treatment and the risk of necrotizing enterocolitis and death in very low birth weight neonates

Antibiotic exposure in the newborn intensive care unit and the risk of necrotizing enterocolitis

Prolonged duration of early antibiotic therapy in extremely premature infants

Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging

Necrotizing enterocolitis: treatment based on staging criteria

Necrotizing enterocolitis

Antibiotic regimens for the empirical treatment of newborn infants with necrotising enterocolitis

A randomized, controlled trial of parenteral clindamycin in neonatal necrotizing enterocolitis

Anaerobic antimicrobial therapy after necrotizing enterocolitis in VLBW infants

A Pharmacoepidemiologic Study of the Safety and Effectiveness of Clindamycin in Infants

A randomized, controlled study of oral gentamicin in the treatment of neonatal necrotizing enterocolitis

Comparison of two antibiotic regimens for neonatal necrotizing enterocolitis

Urinary tract infection in very low birth weight preterm infants

Urinary tract infection in premature infants: the role of imaging studies and prophylactic therapy

Analysis of the efficacy of urine culture as part of sepsis evaluation in the premature infant

Urinary tract infection in preterm infants: the protective role of breastfeeding

Urine culture in the evaluation of suspected neonatal sepsis

Urinary tract infection in outpatient febrile infants younger than 30 days of age: a 10-year evaluation

Prevalence of vesicoureteral reflux in neonatal urinary tract infection

First urinary tract infection in neonates, infants and young children: a comparative study

66 infants with urinary tract infection in first month of life

Urinary tract infection concordance with positive blood and cerebrospinal fluid cultures in the neonatal intensive care unit

Outcomes following candiduria in extremely low birth weight infants

Clinical and demographic factors associated with urinary tract infection in young febrile infants

Urinary tract infection in infants less than 2 months of age

The changing epidemiology of serious bacterial infections in young infants

Prevalence of renal anomalies after urinary tract infections in hospitalized infants less than 2 months of age

Neonatal candidiasis: epidemiology, risk factors, and clinical judgment

Prevalence of Candida species in hospital-acquired urinary tract infections in a neonatal intensive care unit

Urinary tract infections in the infant

Urinary tract infections in young febrile children

Urine culture from bag specimens in young children: are the risks too high?

Is urethral catheterization a successful alternative to suprapubic aspiration in neonates? J Paediatr Child Health

Comparison of pain during two methods of urine collection in preterm infants

Diagnosis of Urinary Tract Infections in Children

Diagnostic performance of urine dipstick testing in children with suspected UTI: a systematic review of relationship with age and comparison with microscopy

Febrile urinary tract infections in 0-to 3-month-old infants: a prospective follow-up study

Gentamicin resistance among Escherichia coli strains isolated in neonatal sepsis

Genotypic and phenotypic characterization of invasive neonatal Escherichia coli clinical isolates

Frequency and Susceptibility of Bacteria Caused Urinary Tract Infection in Neonates: Eight-Year Study at Neonatal Division of Bahrami Children's Hospital, Tehran Iran

In vitro assessment of urinary isolates of ampicillin-resistant enterococci

Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months

Guidelines for Preventing Health-Care-Associated Pneumonia

The difficulty of diagnosing ventilator-associated pneumonia

Ventilator-associated pneumonia in newborn infants diagnosed with an invasive bronchoalveolar lavage technique: a prospective observational study

Study of Ventilator Associated Pneumonia in Neonatal Intensive Care Unit: characteristics, risk factors and outcome

Ventilator-associated pneumonia in extremely preterm neonates in a neonatal intensive care unit: characteristics, risk factors, and outcomes

Nosocomial infections in a Dutch neonatal intensive care unit: surveillance study with definitions for infection specifically adapted for neonates

Risk factors and outcomes for ventilator-associated pneumonia in neonatal intensive care unit patients

Neonatal pneumonia

Surveillance of ventilator-associated pneumonia in very-low-birth-weight infants

Strategies to prevent ventilator-associated pneumonia in neonates

Sensitivity, specificity, and predictive value of body surface cultures in a neonatal intensive care unit

Purulence and gram-negative bacilli in tracheal aspirates of mechanically ventilated very low birth weight infants

The utility of tracheal aspirate cultures in the immediate neonatal period

Ventilator-associated pneumonia in neonatal patients: an update

Cell Count Analysis from Nonbronchoscopic Bronchoalveolar Lavage in Preterm Infants

Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

Use of colistin for the treatment of multi drug resistant isolates in neonates

Safety in treatment of ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii with aerosolized colistin in neonates: a preliminary report

Neonatal pneumonia: comparison of 4 vs 7 days of antibiotic therapy in term and near-term infants

Prospective surveillance of antibiotic use in the neonatal intensive care unit: results from the SCOUT study

Cardiopulmonary and intracranial pressure changes related to endotracheal suctioning in preterm infants

Comparison of a closed (Trach Care MAC) with an open endotracheal suction system in small premature infants

Prospective surveillance of nosocomial infections in a Swiss NICU: low risk of pneumonia on nasal continuous positive airway pressure?

Heated humidified high-flow nasal cannula: use and a neonatal early extubation protocol

Reduction of nosocomial infection in a neonatal intensive care unit (NICU)

Handwashing program for the prevention of nosocomial infections in a neonatal intensive care unit

Drug Dosages

Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design

Comparative Analysis of Ampicillin Plasma and Dried Blood Spot Pharmacokinetics in Neonates

Population Pharmacokinetics and Dosing Considerations for Gentamicin in Newborns with Suspected or Proven Sepsis Caused by Gram-Negative Bacteria

Predictive performance of a gentamicin population pharmacokinetic model in neonates receiving full-body hypothermia

Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling

A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants

Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates

Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age

Population pharmacokinetics of piperacillin using scavenged samples from preterm infants

Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants

Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants

Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance

Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice

Effect of Donor Milk on Severe Infections and Mortality in Very Low-Birth-Weight Infants: The Early Nutrition Study Randomized Clinical Trial

Randomized trial of exclusive human milk versus preterm formula diets in extremely premature infants

An exclusively human milk-based diet is associated with a lower rate of necrotizing enterocolitis than a diet of human milk and bovine milk-based products

Feeding strategies for premature infants: beneficial outcomes of feeding fortified human milk versus preterm formula

The effect of early administration of combined multi-strain and multi-species probiotics on gastrointestinal morbidities and mortality in preterm infants: A randomized controlled trial in a tertiary care unit

Probiotic effects on late-onset sepsis in very preterm infants: a randomized controlled trial

Efficacy of Bifidobacterium breve and Lactobacillus casei oral supplementation on necrotizing enterocolitis in very-low-birth-weight preterm infants: a double-blind, randomized, controlled trial

Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial